ImageneBio, Inc. Operating Income
ImageneBio, Inc. (IMA) reported Operating Income of -$11.78 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2026-08-05
- ImageneBio, Inc. operating income (loss) for the quarter ending 2026-06-30 was -$11.78M.
- ImageneBio, Inc. operating income (loss) for the quarter ending 2026-03-31 was -$12.08M.
- ImageneBio, Inc. operating income (loss) for the quarter ending 2025-12-31 was -$8.50M.
- ImageneBio, Inc. operating income (loss) for the quarter ending 2025-09-30 was -$26.59M.
- ImageneBio, Inc. operating income (loss) for fiscal 2025 was -$48.45M.
- ImageneBio, Inc. operating income (loss) for fiscal 2024 was -$37.00M.
- ImageneBio, Inc. operating income (loss) for fiscal 2023 was -$75.42M.
- ImageneBio, Inc. operating income (loss) for fiscal 2022 was -$70.90M.
| Period end | Operating Income (Loss) 3 month | Operating Income (Loss) 3 month as first filed | Operating Income (Loss) 6 month | Operating Income (Loss) 6 month as first filed | Operating Income (Loss) 9 month | Operating Income (Loss) 9 month as first filed | Operating Income (Loss) 12 month | Operating Income (Loss) 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$11.78M 10-Q · filed 2026-08-05 | -$23.86M 10-Q · filed 2026-08-05 | -$32.37M derived: sum of 3 quarters · filed 2026-08-05 | -$58.96M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2026-03-31 | -$12.08M 10-Q · filed 2026-05-07 | -$20.58M derived: sum of 2 quarters · filed 2026-05-07 | -$47.18M derived: sum of 3 quarters · filed 2026-05-07 | -$54.53M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-12-31 | -$8.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | -$35.10M derived: sum of 2 quarters · filed 2026-03-10 | -$42.46M derived: sum of 3 quarters · filed 2026-08-05 | -$48.45M 10-K · filed 2026-03-10 | ||||
| 2025-09-30 | -$26.59M 10-Q · filed 2025-11-12 | -$33.95M derived: sum of 2 quarters · filed 2026-08-05 | -$39.95M 10-Q · filed 2025-11-12 | -$46.09M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-06-30 | -$7.36M 10-Q · filed 2026-08-05 | -$8.75M 10-Q · filed 2025-07-24 | -$13.35M 10-Q · filed 2026-08-05 | -$19.54M 10-Q · filed 2025-07-24 | -$19.50M derived: sum of 3 quarters · filed 2026-08-05 | -$21.53M derived: sum of 4 quarters · filed 2026-08-05 | ||
| 2025-03-31 | -$6.00M 10-Q · filed 2026-05-07 | -$10.79M 10-Q · filed 2025-05-08 | -$12.14M derived: sum of 2 quarters · filed 2026-05-07 | -$14.17M derived: sum of 3 quarters · filed 2026-05-07 | -$30.00M derived: sum of 4 quarters · filed 2026-05-07 | |||
| 2024-12-31 | -$6.14M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | -$8.18M derived: sum of 2 quarters · filed 2026-03-10 | -$24.00M derived: sum of 3 quarters · filed 2026-03-10 | -$37.00M 10-K · filed 2026-03-10 | -$58.97M 10-K · filed 2025-03-06 | |||
| 2024-09-30 | -$2.04M 10-Q · filed 2025-11-12 | -$12.41M 10-Q · filed 2024-11-07 | -$17.86M derived: sum of 2 quarters · filed 2025-11-12 | -$30.86M 10-Q · filed 2025-11-12 | -$46.46M 10-Q · filed 2024-11-07 | -$57.99M derived: sum of 4 quarters · filed 2025-11-12 | ||
| 2024-06-30 | -$15.82M 10-Q · filed 2025-07-24 | -$34.05M 10-Q · filed 2025-07-24 | -$55.96M derived: sum of 3 quarters · filed 2025-07-24 | -$75.46M derived: sum of 4 quarters · filed 2025-07-24 | ||||
| 2024-03-31 | -$18.23M 10-Q · filed 2025-05-08 | -$40.13M derived: sum of 2 quarters · filed 2025-05-08 | -$59.64M derived: sum of 3 quarters · filed 2025-05-08 | -$78.13M derived: sum of 4 quarters · filed 2025-05-08 | ||||
| 2023-12-31 | -$21.91M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | -$41.41M derived: sum of 2 quarters · filed 2025-03-06 | -$59.90M derived: sum of 3 quarters · filed 2025-03-06 | -$75.42M 10-K · filed 2025-03-06 | ||||
| 2023-09-30 | -$19.50M 10-Q · filed 2024-11-07 | -$37.99M derived: sum of 2 quarters · filed 2024-11-07 | -$53.51M 10-Q · filed 2024-11-07 | -$68.62M derived: sum of 4 quarters · filed 2024-11-07 | ||||
| 2023-06-30 | -$18.49M 10-Q · filed 2024-08-08 | -$34.01M 10-Q · filed 2024-08-08 | -$49.12M derived: sum of 3 quarters · filed 2024-08-08 | -$67.00M derived: sum of 4 quarters · filed 2024-08-08 | ||||
| 2023-03-31 | -$15.52M 10-Q · filed 2024-05-13 | -$30.63M derived: sum of 2 quarters · filed 2024-05-13 | -$48.51M derived: sum of 3 quarters · filed 2024-05-13 | -$69.46M derived: sum of 4 quarters · filed 2024-05-13 | ||||
| 2022-12-31 | -$15.11M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-12 | -$32.99M derived: sum of 2 quarters · filed 2024-03-12 | -$53.94M derived: sum of 3 quarters · filed 2024-03-12 | -$70.90M 10-K · filed 2024-03-12 | ||||
| 2022-09-30 | -$17.88M 10-Q · filed 2023-11-09 | -$38.83M derived: sum of 2 quarters · filed 2023-11-09 | -$55.79M 10-Q · filed 2023-11-09 | -$53.00M derived: sum of 4 quarters · filed 2023-11-09 | ||||
| 2022-06-30 | -$20.95M 10-Q · filed 2023-08-10 | -$37.91M 10-Q · filed 2023-08-10 | -$35.12M derived: sum of 3 quarters · filed 2023-08-10 | -$49.64M derived: sum of 4 quarters · filed 2023-08-10 | ||||
| 2022-03-31 | -$16.96M 10-Q · filed 2023-05-15 | -$14.17M derived: sum of 2 quarters · filed 2023-05-15 | -$28.69M derived: sum of 3 quarters · filed 2023-05-15 | -$41.38M derived: sum of 4 quarters · filed 2023-05-15 | ||||
| 2021-12-31 | $2.79M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-14 | -$11.73M derived: sum of 2 quarters · filed 2023-03-14 | -$24.42M derived: sum of 3 quarters · filed 2023-03-14 | -$34.14M 10-K · filed 2023-03-14 | ||||
| 2021-09-30 | -$14.52M 10-Q · filed 2022-11-07 | -$27.21M derived: sum of 2 quarters · filed 2022-11-07 | -$36.93M 10-Q · filed 2022-11-07 | -$62.98M derived: sum of 4 quarters · filed 2022-11-07 | ||||
| 2021-06-30 | -$12.69M 10-Q · filed 2022-08-11 | -$22.41M 10-Q · filed 2022-08-11 | -$48.46M derived: sum of 3 quarters · filed 2022-08-11 | -$54.69M derived: sum of 4 quarters · filed 2022-08-11 | ||||
| 2021-03-31 | -$9.72M 10-Q · filed 2022-05-12 | -$35.77M derived: sum of 2 quarters · filed 2022-05-12 | -$42.01M derived: sum of 3 quarters · filed 2022-05-12 | -$47.06M derived: sum of 4 quarters · filed 2022-05-12 | ||||
| 2020-12-31 | -$26.05M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | -$32.29M derived: sum of 2 quarters · filed 2022-03-17 | -$37.34M derived: sum of 3 quarters · filed 2022-03-17 | -$44.52M 10-K · filed 2022-03-17 | ||||
| 2020-09-30 | -$6.23M 10-Q · filed 2021-11-10 | -$11.29M derived: sum of 2 quarters · filed 2021-11-10 | -$18.47M 10-Q · filed 2021-11-10 | |||||
| 2020-06-30 | -$5.06M 10-Q · filed 2021-08-12 | -$12.23M 10-Q · filed 2021-08-12 | ||||||
| 2020-03-31 | -$7.18M 10-Q · filed 2021-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B |